Modality
Radioligand
MOA
PARPi
Target
TIM-3
Pathway
Tau
NBAMLGIST
Development Pipeline
Preclinical
Sep 2019
→ Jan 2031
PreclinicalCurrent
NCT05249398
889 pts·GIST
2019-09→2031-01·Recruiting
889 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-01-054.8y awayInterim· GIST
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
Preclinical
Recruit…
Catalysts
Interim
2031-01-05 · 4.8y away
GIST
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05249398 | Preclinical | GIST | Recruiting | 889 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 |